Status:
COMPLETED
Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation
Lead Sponsor:
The University of Hong Kong
Conditions:
Hematological Diseases
Eligibility:
All Genders
18+ years
Brief Summary
Haemopoietic stem cell transplantation (HSCT) has become a major life-saving treatment for many haematological conditions, mostly malignancies. However, there are lots of potential complications that...
Detailed Description
Haemopoietic stem cell transplantation (HSCT) has revolutionized the treatment of both haematological and perhaps some solid malignancies. However, despite recent technological advancements, HSCT is s...
Eligibility Criteria
Inclusion
- Haematological conditions requiring HSCT (either autologous or allogeneic with sibling donor), post-HSCT BOS, or healthy HSCT donors
- Life expectancy \> 12 weeks
Exclusion
- Respiratory failure requiring use of supplemental oxygen therapy
- Known airway diseases including asthma, chronic obstructive pulmonary disease and bronchiectasis
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
228 Patients enrolled
Trial Details
Trial ID
NCT00956358
Start Date
March 1 2009
End Date
December 1 2015
Last Update
May 12 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, Hong Kong